Skip to main content

Alzheimer Disease, ARIA & Dementia Study Group Webinar: Practical Reflections for Lecanemab

Alzheimer Disease, ARIA & Dementia Study Group Webinar: Practical Reflections for Lecanemab

Description & Learning Objectives
Planned and presented by the Alzheimer's/ARIA/Dementia Study Group, with Tammie Benzinger, MD, PhD moderating.

Upon completion of this activity, participants will gain strategies to:
1. Understand implications of lecanemab therapy for Alzheimer disease in the US.
2. Describe how patients undergoing Alzheimer disease therapy with lecanemab might need radiology services including: Brain MRI, Lumbar Puncture, and Amyloid PET.
3. Compare strategies for different healthcare environments such as: Academic practice, Hybrid academic/private practice, Private practice, and Geographical / regional differences.
Instructions for Participation
To complete this activity, learners will watch a recording of a live webinar and submit a course evaluation. Once all elements are completed, a certificate will be automatically added to your transcript.
Credit Dates
Available: 8/18/2023
Expires: 8/17/2026

Planners & Faculty
Tammie Benzinger, MD, PhD, Planner/Moderator
Petrice Cogswell, MD, PhD, Planner/Speaker
Suzie Bash, MD, Speaker
Gregg Day, MD, Speaker
Ana Franceschi, MD, PhD, Speaker

Accreditation Statement
The American Society of Neuroradiology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Neuroradiology designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In compliance with ACCME requirements and guidelines, ASNR has developed a policy for disclosure and review of potential conflicts of interest and a method for resolution if a conflict does exist. ASNR maintains a tradition of scientific integrity and objectivity in its educational activities. In order to preserve these values and ensure its educational activities are independent and free of commercial bias, all individuals, including planners, presenters, moderators and evaluators, participating in an ASNR educational activity, or an activity jointly provided by ASNR must disclose all relevant financial relationships with ineligible companies, as defined by the ACCME. Unless listed below, all planners and individuals in control of content have nothing to disclose.

Tammie Benzinger is the Imaging Core Leader for the DIAN-TU, which now includes lecanemab in an ongoing clinical trial, and has participated as a site investigator in clinical trials sponsored by Biogen, Eisai, Eli Lilly, Jansen, and Roche. Has research funding from the NIH and Siemens. Is a consultant to Biogen, Eisai, Eli Lilly, and Bristol Myers Squibb. Dr. Benzinger's employer, Washington University, holds shares in C2N.

Suzie Bash has relationships with Subtle Medical,,, Darmiyan, Merit, Columbo, GE.

Gregg Day is a consultant for Parabon Nanolabs Inc and Topic Editor (Dementia) for DynaMed (EBSCO). He is the co-Project PI for a clinical trial in anti-NMDAR encephalitis, which receives support from Horizon Pharmaceuticals. He has developed educational materials for PeerView Media, Inc, and Continuing Education Inc. He owns stock in ANI pharmaceuticals. Dr. Day’s institution has received support from Eli Lilly for development and participation in an educational event and in-kind contributions of radiotracer precursors for tau-PET neuroimaging in studies of memory and aging (via Avid Radiopharmaceuticals—a wholly-owned subsidiary of Eli Lilly).

Ana Franceschi serves as a consultant for Biogen, Life Molecular Imaging, and Roche/Genentech.

All other participants and planners have no disclosures.

This activity is generously supported by unrestricted educational grants from Eisai & Icometrix.
Other Resources